Mehrdad Mobasher’s Post

#News for #Investors and #Media: As the chronic lymphocytic leukemia (CLL) treatment landscape continues to evolve, it’s important to provide new data that can help physicians in making treatment decisions.  During #ASCO24, we will share new comparative effectiveness research underscoring the differentiated clinical profile of our BTK inhibitor in the treatment of #CLL. Learn more here: https://bit.ly/3Kf9t33

Missed our December webcast about Chronic Lymphocytic Leukemia (CLL)? The recording is now available online, offering valuable insights into CLL. Join Dr. Versha Banerji as she explores the latest in CLL diagnosis, treatment, and future developments. 👉 Watch the recording here: https://bit.ly/48FjIIs #cll #chroniclymphocyticleukemia #bloodcancer #webcast #webinar

In this interview, Neil E. Kay, MD, offers insights into the pathobiology, treatment, and management of double refractory chronic lymphocytic leukemia (CLL). "For most patients who are double refractory, treatment with clinically approved agents [is] short-lived. So clinical trials are probably the best way to treat your double refractory CLL patient if you have one," said Dr Kay. Access the full interview here: https://lnkd.in/eB_Qqxka #JournalofClinicalPathways #JCP #Chroniclymphocyticleukemia #CLL #CLLclincialtrials

Today at #ASCO24, we are excited to be presenting new data on the relapsed / refractory chronic lymphocytic leukemia (#CLL) landscape. Alongside data from head-to-head clinical trials, this research will help to arm physicians with strong, clinically relevant data to help support decision-making for their patients. Learn more about our commitment to #bloodcancers like #CLL. https://bit.ly/3yrtEZ5

Want to learn more about managing patients with chronic lymphocytic leukemia (CLL)? Watch this new sponsored video on updates in CLL: https://lnkd.in/dPK39eyV #LeukemiaAwareness #CLL

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia https://lnkd.in/eAZrMcgy

In a recent WebMD interview, Winship hematologist Andres Chang, MD, PhD, discusses what happens when Chronic lymphocytic leukemia (CLL) comes back. At first, symptoms of a relapse are rare, so watchful waiting is often the approach. Then, there are several paths available, including targeted therapies. Learn more: https://lnkd.in/eDtuNWy4

Receive essential information on chronic lymphocytic leukemia (CLL) treatment in our sponsored, engaging video. Dive into the 5-year off-treatment analyses and discover the long-term effectiveness and safety of a treatment approach. https://lnkd.in/dPK39eyV

📢 View the short video below on important factors to consider when you're looking for treatment options for your patients with CLL. #LEUKEMIA #Oncology #llmcongress2024 #education #knowledge #CLL

Actimab-A is a novel targeted #radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia. We recently highlighted data at #SNMMI24. Dive into the details here: https://bit.ly/3Ro0ikZ